VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101.2 EUR | +1.91% |
|
+3.16% | -1.17% |
| 30/04 | Vetoquinol: down after sales update | CF |
| 29/04 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
ETFs positioned on Vetoquinol SA
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.26% | - |
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
28/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
99.3
EUR
Average target price
105.7
EUR
Spread / Average Target
+6.41%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.37% | 1.28B | |
| -11.98% | 79.26B | |
| +25.75% | 3.74B | |
| -0.28% | 3.27B | |
| +14.36% | 1.69B | |
| -6.22% | 1.56B | |
| -23.36% | 1.29B | |
| -12.76% | 1.14B | |
| +0.79% | 1.06B | |
| -6.98% | 1.01B |
- Stock Market
- Equities
- VETO Stock
- Funds and ETFs Vetoquinol SA
